Pneumocystis jirovecii pneumonia in two patients with systemic lupus erythematosus after rituximab therapy

New cases of Pneumocystis jirovecii pneumonia (PJP) have recently been reported in patients with systemic lupus erythematosus (SLE) after rituximab therapy. Several factors may contribute to susceptibility to P. jirovecii infection in this type of patients, including the immunological characteristic...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical rheumatology 2014-03, Vol.33 (3), p.415-418
Hauptverfasser:	Bonilla-Abadía, F, Betancurt, J F, Pineda, J C, Vélez, J D, Tobón, G J, Cañas, C A
Format:	Artikel
Sprache:	eng
Schlagworte:	Anti-Bacterial Agents - therapeutic use Antibodies, Monoclonal, Murine-Derived - adverse effects Antibodies, Monoclonal, Murine-Derived - therapeutic use Brief Report Fatal Outcome Female Humans Lupus Erythematosus, Systemic - complications Lupus Erythematosus, Systemic - drug therapy Medicine Medicine & Public Health Pneumocystis Pneumocystis carinii - isolation & purification Pneumonia, Pneumocystis - drug therapy Pneumonia, Pneumocystis - etiology Rheumatology Rituximab Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	New cases of Pneumocystis jirovecii pneumonia (PJP) have recently been reported in patients with systemic lupus erythematosus (SLE) after rituximab therapy. Several factors may contribute to susceptibility to P. jirovecii infection in this type of patients, including the immunological characteristics of the disease, the mechanisms of rituximab action, environmental factors, and the biological characteristics of the fungus. We report two patients with SLE who developed PJP after rituximab therapy.
ISSN:	0770-3198 1434-9949
DOI:	10.1007/s10067-013-2475-0